REGENXBIO Inc. (RGNX): Price and Financial Metrics
RGNX Price/Volume Stats
| Current price | $16.25 | 52-week high | $28.80 |
| Prev. close | $16.06 | 52-week low | $11.83 |
| Day low | $15.72 | Volume | 74,887 |
| Day high | $16.40 | Avg. volume | 711,762 |
| 50-day MA | $19.81 | Dividend yield | N/A |
| 200-day MA | $17.79 | Market Cap | 796.95M |
RGNX Stock Price Chart Interactive Chart >
REGENXBIO Inc. (RGNX) Company Bio
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company was founded in 2009 and is based in Rockville, Maryland.
Latest RGNX News From Around the Web
Below are the latest news stories about REGENXBIO INC that investors may wish to consider to help them evaluate RGNX as an investment opportunity.
Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 SharesKenneth Mills, President and CEO of Regenxbio Inc (NASDAQ:RGNX), executed a sale of 45,000 shares in the company on December 19, 2023, according to a recent SEC Filing. |
REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® TrialREGENXBIO Inc. (Nasdaq: RGNX) today announced that the first patient received RGX-202 at dose level 2 in the Phase I/II AFFINITY DUCHENNE® trial. RGX-202 is an investigational one-time AAV Therapeutic for Duchenne muscular dystrophy (Duchenne), using the NAV® AAV8 vector to deliver a transgene for a novel microdystrophin that includes the functional elements of the C-Terminal (CT) domain as well as a muscle-specific promoter to support a targeted therapy for improved resistance to muscle damage |
Wall Street Analysts Believe Regenxbio (RGNX) Could Rally 95.61%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 95.6% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
REGENXBIO (NASDAQ:RGNX) adds US$111m to market cap in the past 7 days, though investors from five years ago are still down 72%REGENXBIO Inc. ( NASDAQ:RGNX ) shareholders should be happy to see the share price up 16% in the last week. But will... |
REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call TranscriptREGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript November 8, 2023 REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.41, expectations were $-1.44. Operator: Good day, and thank you for standing by. Welcome to REGENXBIO’s Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, […] |
RGNX Price Returns
| 1-mo | -26.74% |
| 3-mo | 27.75% |
| 6-mo | 13.00% |
| 1-year | -12.87% |
| 3-year | -53.45% |
| 5-year | -69.13% |
| YTD | -9.47% |
| 2023 | -20.86% |
| 2022 | -30.64% |
| 2021 | -27.91% |
| 2020 | 10.72% |
| 2019 | -2.34% |
Continue Researching RGNX
Want to do more research on REGENXBIO Inc's stock and its price? Try the links below:REGENXBIO Inc (RGNX) Stock Price | Nasdaq
REGENXBIO Inc (RGNX) Stock Quote, History and News - Yahoo Finance
REGENXBIO Inc (RGNX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...